Flurazepam inhibits the P-glycoprotein transport function: an insight to revert multidrug-resistance phenotype

European Journal of Pharmacology
Sofia A C LimaAnabela Cordeiro-da-Silva

Abstract

P-glycoprotein mediated drug transport may lead to a multidrug resistance phenotype often associated with a poor response to the successful treatment of a variety of human disorders. Several agents have been found to modulate P-glycoprotein drug resistance, most probably by blocking its transport function. The aim of this study was to examine the effects of some benzodiazepines (bromazepam, chlordiazepoxide, diazepam and flurazepam) able to bind to P-glycoprotein in proteoliposomes on its transport function and ATPase activity in the human cancer cell line, KB-V1. The toxicity of the benzodiazepines drugs towards KB-V1 cells was first evaluated and the non toxic drugs concentrations were used to assess the drug efflux and the ATPase activity. Using the flow cytometry approach, the accumulation and efflux of daunorubicin were followed by measuring the daunorubicin associated geometric mean fluorescence intensity. Vanadate was employed as a comparative inhibitory compound. Flurazepam was able to inhibit the daunorubicin efflux in 80%. ATPase activity determined by a colorimetric assay revealed that flurazepam inhibits the P-glycoprotein enzymatic activity, indicating coupling between drug transport and ATP hydrolysis. Bromazepam,...Continue Reading

References

Dec 1, 1979·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·A Krishan, R Ganapathi
Nov 11, 1976·Biochimica Et Biophysica Acta·R L Juliano, V Ling
Sep 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·S V AmbudkarI Pastan
Jan 16, 1991·Journal of the National Cancer Institute·G D PennockS E Salmon
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·F ThiebautM C Willingham
May 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·M HorioI Pastan
Mar 29, 1985·Biochemical and Biophysical Research Communications·S Abou-KhalilT J Lampidis
Nov 10, 1995·The Journal of Biological Chemistry·I L UrbatschA E Senior
Sep 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B I Sikic
Jun 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G A FisherB I Sikic
Jun 1, 1997·Seminars in Cancer Biology·A E Senior, D C Gadsby
Sep 6, 2000·British Journal of Haematology·R J Arceci
Dec 26, 2001·Antimicrobial Agents and Chemotherapy·Er-jia WangWilliam W Johnson
Sep 29, 2004·Nature Structural & Molecular Biology·Christopher F Higgins, Kenneth J Linton
Mar 5, 2005·Analytical Biochemistry·Sofia A C LimaBaltazar de Castro
Dec 15, 2005·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Suresh V AmbudkarZuben E Sauna
Aug 22, 2006·Biophysical Chemistry·Sofia A C LimaPaula Gameiro

❮ Previous
Next ❯

Citations

Nov 14, 2013·Journal of Toxicology and Environmental Health. Part B, Critical Reviews·Susan S Schiffman, Kristina I Rother
May 24, 2011·Toxicology Letters·Marloes J A JoosenHerman P M van Helden

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.